已核实 DOI PubMed 相关产品: 227

H2S-Activable BiFeO3–x Nanocatalysts for Ferroptosis-Driven Cancer Immunotherapy

Journal 2026 · IF 17.3 · 发表于 2026 年 2 月 2 日
作者: Jinzhe Liang,Xianliu Luo,Ya-Qian Shi,Liang-Mei Yang,Caiying Li,Lixian Huang,Yuzhen Ma,Yong Huang,Shulin Zhao
阅读全文 在 PubMed 查看

摘要

Controlling ferroptosis through material redox dynamics represents a frontier in the field of catalytic nanomedicine. Here, we introduce nonstoichiometric bismuth ferrite (BiFeO3–x) as an H2S-activable semiconductor that couples oxygen-vacancy-enabled charge modulation with endogenous sulfur chemistry to achieve spatiotemporally controlled immunogenic ferroptosis. Upon exposure to tumor-enriched gasotransmitter H2S, BiFeO3–x undergoes a transformation into Bi2S3 while releasing Fe2+ ions to trigger Fenton-like lipid peroxidation. The material’s mixed-valence Fe redox pair amplifies reactive oxygen species generation under 808 nm excitation, coupling photothermal energy dissipation with catalytic ferroptotic stress. Biologically, this multiresponse process initiates mitochondrial collapse, glutathione peroxidase 4 depletion, and lipid peroxide accumulation, driving apoptosis–ferroptosis cascades. In vivo, photoacoustic-guided therapy and mass cytometry profiling reveal profound immune remodeling, such as dendritic cell maturation, CD8+ T cell infiltration, and M1 macrophage polarization, implying the conversion of “cold” colorectal tumors into immunogenic tumor microenvironments. This work establishes a defect-chemistry-oriented design framework for engineering redox-programmable nano semiconductors that translate lattice instability into biological selectivity, bridging ferroelectric materials science and immune oncology.

本研究中使用的阿拉丁产品

227 款产品在本文中被引用